Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.

Trial Profile

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2014

At a glance

  • Drugs Lapatinib (Primary) ; Hormones; Metformin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2012 New source identified and integrated (European Clinical Trials Database record).
    • 24 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top